DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Abaloparatide
OtherFDA approvedRx required

Abaloparatide

Also known as: Tymlos
Brands: Tymlos

Synthetic 34-amino-acid analog of PTHrP approved for postmenopausal osteoporosis.

A
Grade A
Multiple human RCTs
Human studies28
PubMed citations29
Routesubcutaneous
Regulatory (US)FDA approved · Rx
Last verified2 days ago

Mechanism of action

Selective activator of the PTH1 receptor conformation favoring bone formation (RG vs R0). Anabolic effect on bone.

Evidence summary

28
Human studies
29
PubMed citations
23
Clinical trials
A
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

From the FDA label
Source
abdominal painarthralgiaastheniaconstipationdecreased appetitediarrheadizzinessfatigueheadacheinjection site erythemainjection site paininsomnianauseapalpitationspruritusrashtachycardiavomiting

Terms pulled directly from the referenced source. We don't fabricate frequencies — when a label doesn't publish a percentage, we don't either.

Interactions

No documented drug interactions on file.

Regulatory status

United States
FDA approved

FDA approved for postmenopausal osteoporosis at high fracture risk (Tymlos)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT03841058Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion SurgeryRecruiting · Phase 2 · Spinal Fusion · n=96NCT04467983Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneActive Not Recruiting · Phase 4 · Osteoporosis, Postmenopausal · n=70NCT06164795Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) StudyRecruiting · Osteoporosis, Postmenopausal · n=150NCT04167163An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee ArthroplastyCompleted · Phase 4 · Osteoporosis · n=58NCT06898060A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of FractureNot Yet Recruiting · Phase 3 · Postmenopausal Women With Osteoporosis · n=282NCT06753864A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult SubjectsNot Yet Recruiting · Phase 1 · Osteoporosis · n=32NCT04760782Effect of PTH Analog on Union Rates of Type II Odontoid Fractures in Older AdultsTerminated · Phase 2 · Odontoid Fracture · n=22NCT04249232Abaloparatide Versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled TrialCompleted · Phase 2 · Fracture of Pelvis (Disorder) · n=48NCT04626141Time to Healing, Loss of Fixation, and Loss of Alignment in Supracondylar Distal Femur Fractures Among a Geriatric Population Treated With Abaloparatide: A Double-Blind Placebo Controlled StudyWithdrawn · Phase 4 · Femoral FracturesNCT04974723A Retrospective, Observational Cohort Study Evaluating the Effectiveness and Cardiovascular Safety of Abaloparatide in Postmenopausal Women New to Anabolic TherapiesCompleted · Osteoporosis, Postmenopausal · n=22054NCT06154187A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With OsteoporosisUnknown · Phase 3 · Osteoporosis · n=60NCT04366726A Prospective, Single Arm Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Usability of Abaloparatide-sMTS in Postmenopausal Women With Low Bone Mineral DensityCompleted · Phase 1 · Postmenopausal Osteoporosis · n=22

Showing 12 of 23 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41598611Bonifacio M, Ruggiero M et al. · The Efficacy and Safety of Abaloparatide in Osteoporosis: A Systematic Review and Meta-Analysis.Journal of clinical medicine (2026)PMID 41252575Sølling AS, Langdahl BL et al. · Recent Advances in Osteoporosis Therapeutics.Annual review of medicine (2026)HumanPMID 40587168Morin SN, Leslie WD et al. · Osteoporosis: A Review.JAMA (2025)HumanPMID 39009890Ebina K, Etani Y et al. · Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.Journal of bone and mineral metabolism (2025)HumanPMID 41114847Stumpf U, Kurth A · [Osteo-anabolic treatment strategies].Orthopadie (Heidelberg, Germany) (2025)HumanPMID 40921943Gregson CL, Armstrong DJ et al. · The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.Archives of osteoporosis (2025)HumanPMID 40790089Fuggle N, Rizzoli R et al. · Parathyroid hormone receptor agonists in the management of osteoporosis.Nature reviews. Rheumatology (2025)HumanPMID 39172879Anderson PA, Kates SL et al. · Update on Atypical Femoral Fractures.The Journal of bone and joint surgery. American volume (2025)HumanPMID 38107815Sauhta R, Makkar D et al. · The Sequential Therapy in Osteoporosis.Indian journal of orthopaedics (2024)HumanPMID 39120740Veronese N, Briot K et al. · Recommendations for the optimal use of bone forming agents in osteoporosis.Aging clinical and experimental research (2024)HumanPMID 38307725Xu F, Wang Y et al. · The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.Clinical therapeutics (2024)HumanPMID 39448133di Filippo L, Rosen CJ · Latest on Anabolic Agents for Osteoporosis Treatment.Endocrinology and metabolism clinics of North America (2024)HumanPMID 36592455Ayers C, Kansagara D et al. · Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Annals of internal medicine (2023)HumanPMID 36658750Liu W, Lee B et al. · Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.The Journal of clinical endocrinology and metabolism (2023)HumanPMID 36920813Harris K, Zagar CA et al. · Osteoporosis: Common Questions and Answers.American family physician (2023)HumanPMID 37130601Händel MN, Cardoso I et al. · Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.BMJ (Clinical research ed.) (2023)HumanPMID 35279261Reid IR, Billington EO · Drug therapy for osteoporosis in older adults.Lancet (London, England) (2022)HumanPMID 36382762Chandran M · The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.Archives of endocrinology and metabolism (2022)HumanPMID 35478046LeBoff MS, Greenspan SL et al. · The clinician's guide to prevention and treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)HumanPMID 36210087McConnell M, Shieh A · Polypharmacy in Osteoporosis Treatment.Clinics in geriatric medicine (2022)Human

Showing 20 of 29 papers. View all on PubMed →